Krystal Biotech stock
KRYSNASDAQKrystal Biotech, Inc., HealthcareISIN US5011471027
66Score 66 out of 100, Neutral
Price and trend
58 / 100
Price history
+51% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.3% below it.
Since October 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 19% below its 52-week high. Largest decline in 9 years: 53% (March 2021 to November 2021).
Chart figures for advanced users
- SMA 50$328.09
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$309.58
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$201.21
- The lowest closing price of the last twelve months.
- Resistance$378.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Krystal Biotech, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $9.06B, is number 43 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $389.13M (up 33.9% year on year) and earnings of $204.83M (up 129.7%).
- For fiscal 2026, analysts expect on average revenue of $497.5M (up 27.9%) and adjusted earnings per share of $7.67 (up 12%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 200 of 702 in Healthcare, median 53.
- The P/E is 41.9 (Biotechnology median 21.7, own median of recent years 42.5).
- Our model puts fair value at $411.89, with the price 26% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 47.9% over the last 12 months, Biotechnology median −103.7%.Profitability 93
- High return on capitalReturn on invested capital 42.6% in fiscal 2025, Biotechnology median −24.3%.Profitability 93
- More cash than debtCash $911.85M, financial debt $8.59M.Stability 86
Weaknesses
- DilutionShare count up 54% since 2020.Capital allocation 54
Its standout strengths are profitability and stability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $294.20 and expensive above $686.48 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $665.18 (cash-flow model) and $158.59 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $351.66, at 8.2% it would be $500.19.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 26% on the twelve months before. Revenue has grown strongly since 2023, at around 177% per year. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating 41%, net 53%. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 16 Feb 2027in 95 days
- Last reported
- 2 Nov 2026EPS reported $2.05 (expected $1.79)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 3.0% since 15 Oct 2026.
- Earnings per share
- $7.67+3.0%
- Revenue
- $497.5M−0.6%
- Earnings per share
- $9.27+0.3%
- Revenue
- $646.3M−1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.8%Non-GAAP operating expense guidance unchanged; continued growth in patients and several trial milestones are expected before year end.
“We expect to enroll approximately 5 patients and report interim results before year-end.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $42.14M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Krishnan SumaSale
4 Sept 2026, 10 percent owner, officer: President, R&D
- Shares
- 25,000
- Price
- $359.32
- Value
- $8.98M
- Krishnan Krish SSale
4 Sept 2026, 10 percent owner, officer: President and CEO
- Shares
- 25,000
- Price
- $359.32
- Value
- $8.98M
- Rossi Dino ASale
14 Aug 2026, Board
- Shares
- 25,000
- Price
- $329.12
- Value
- $8.23M
Show 4 more
- Thomas John CharlesSale
25 Jun 2026, EVP, General Counsel
- Shares
- 1,000
- Price
- $347.27
- Value
- $347,270
- Krishnan SumaSale
4 Jun 2026, 10 percent owner, officer: President, R&D
- Shares
- 25,000
- Price
- $308.11
- Value
- $7.7M
- Krishnan Krish SSale
4 Jun 2026, 10 percent owner, officer: President and CEO
- Shares
- 25,000
- Price
- $308.12
- Value
- $7.7M
- Thomas John CharlesSale
26 May 2026, EVP, General Counsel
- Shares
- 642
- Price
- $302.03
- Value
- $193,903
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Krystal Biotech
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- TG TherapeuticsTGTX $9.76B66
- Alteogen196170.KQ $9.26B57
- Genscript Biotech1548.HK $9.09B48
- Praxis Precision MedicinesPRAX $9.08B42
- Protagonist TherapeuticsPTGX $8.77B68
- Asymchem Laboratories (Tianjin)002821.SZ $8.29B64
- RemeGen688331.SS $8.26B44
- ALK-AbellóALK-B.CO $8.18B74
ETFs that hold Krystal Biotech
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.58% | 0.35% | €1.25B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.52% | 0.30% | €185.82M |
| Harbor Health Care UCITS ETF AccW311 | 0.51% | 0.89% | €11.72M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.27% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.26% | 0.30% | €2.22B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.24% | 0.30% | €5.36B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.10% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.07% | 0.45% | €1.54B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.